Action IDYA IDEAYA BIOSCIENCES, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues IDEAYA Biosciences, Inc.

Actions

IDYA

US45166A1025

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 10/06/2024 		Varia. 5j. Varia. 1 janv.
38,33 USD +0,84 % Graphique intraday de IDEAYA Biosciences, Inc. -1,44 % +7,73 %
10/06 Transcript : IDEAYA Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 08:00 AM
04/06 IDEAYA BIOSCIENCES, INC. : Stifel Nicolaus reste à l'achat ZM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
IDEAYA Biosciences, Inc. Announces Results for darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma At Asco and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study
Ideaya Biosciences Insider Sold Shares Worth $1,032,884, According to a Recent SEC Filing
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events
IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024
Ideaya Biosciences Insider Sold Shares Worth $7,397,291, According to a Recent SEC Filing
IDEAYA Biosciences Shares Fall After Q1 Loss
IDEAYA Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4) - April 26, 2024
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
IDEAYA Biosciences Selects Move-Forward Expansion Dose for Mid-Stage Trial of IDE397 Monotherapy
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
IDEAYA Biosciences, Inc. Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA in Patients with Endometrial Cancer
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action IDYA
  4. Actualités IDEAYA Biosciences, Inc.
  5. Autres langues